CALLIDITAS THERAPEUTICS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 106.9 SEK | +3.09% |
|
+6.58% | -15.89% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,930 | 6,972 | 5,904 | 5,507 | 6,822 | 5,566 | - | - |
| Enterprise Value (EV) 1 | 2,177 | 5,976 | 5,162 | 4,971 | 6,815 | 5,441 | 4,373 | 2,365 |
| P/E ratio | -86 x | -14.5 x | -11.5 x | -11.9 x | -14.6 x | 24.5 x | 4.52 x | 2.19 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 15.9 x | 7,977 x | 25.7 x | 6.86 x | 5.65 x | 2.88 x | 1.69 x | 1.17 x |
| EV / Revenue | 11.8 x | 6,837 x | 22.5 x | 6.19 x | 5.65 x | 2.81 x | 1.33 x | 0.5 x |
| EV / EBITDA | -77.8 x | -15.7 x | -9.84 x | -11.8 x | -18.3 x | 23.2 x | 2.9 x | 0.83 x |
| EV / FCF | -24.4 x | -12.4 x | -11.2 x | -15.8 x | - | 23 x | 3.27 x | 0.94 x |
| FCF Yield | -4.09% | -8.06% | -8.94% | -6.31% | - | 4.35% | 30.6% | 107% |
| Price to Book | 3.72 x | 5.18 x | 5.86 x | 6.48 x | 20.4 x | 17.9 x | 5.81 x | 2.01 x |
| Nbr of stocks (in thousands) | 38,708 | 49,942 | 52,342 | 59,573 | 53,672 | 53,672 | - | - |
| Reference price 2 | 75.70 | 139.6 | 112.8 | 92.45 | 127.1 | 103.7 | 103.7 | 103.7 |
| Announcement Date | 14/02/20 | 18/02/21 | 24/02/22 | 23/02/23 | 21/02/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 184.8 | 0.874 | 229.3 | 802.9 | 1,207 | 1,935 | 3,295 | 4,747 |
| EBITDA 1 | -27.98 | -379.7 | -524.5 | -421.9 | -373.1 | 234.2 | 1,508 | 2,850 |
| EBIT 1 | -28.02 | -379.7 | -524.5 | -421.9 | -373.1 | 178.7 | 1,294 | 2,430 |
| Operating Margin | -15.16% | -43,446.22% | -228.67% | -52.55% | -30.91% | 9.23% | 39.27% | 51.18% |
| Earnings before Tax (EBT) 1 | -32.5 | -436.2 | -513.4 | -409.4 | -457 | 101.5 | 1,256 | 2,398 |
| Net income 1 | -32.58 | -433.5 | -500.3 | -412.3 | -466.2 | 85.39 | 1,090 | 2,016 |
| Net margin | -17.63% | -49,598.86% | -218.14% | -51.35% | -38.63% | 4.41% | 33.08% | 42.46% |
| EPS 2 | -0.8800 | -9.660 | -9.840 | -7.780 | -8.690 | 4.235 | 22.93 | 47.33 |
| Free Cash Flow 1 | -89.08 | -481.8 | -461.6 | -313.9 | - | 236.6 | 1,337 | 2,526 |
| FCF margin | -48.2% | -55,124.49% | -201.26% | -39.09% | - | 12.23% | 40.56% | 53.22% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 101.03% | 88.64% | 88.66% |
| FCF Conversion (Net income) | - | - | - | - | - | 277.14% | 122.62% | 125.32% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 14/02/20 | 18/02/21 | 24/02/22 | 23/02/23 | 21/02/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 198.2 | 31.2 | 49.73 | 64 | 260.1 | 429 | 191.4 | 269.4 | 294.6 | 451.6 | 383.1 | 434.5 | 515.8 | 622.2 |
| EBITDA 1 | 7.856 | -222.1 | -208.4 | -209.8 | -36.23 | 32.5 | -180.1 | -75.17 | -159.6 | 41.76 | -59.9 | -1.933 | 69.87 | 185.9 |
| EBIT 1 | 7.856 | -222.1 | -208.4 | -209.8 | -36.23 | 32.5 | -180.1 | -75.17 | -159.6 | 41.76 | -31.64 | -1.908 | 51.69 | 151.4 |
| Operating Margin | 3.96% | -711.86% | -418.96% | -327.88% | -13.93% | 7.57% | -94.11% | -27.91% | -54.17% | 9.25% | -8.26% | -0.44% | 10.02% | 24.33% |
| Earnings before Tax (EBT) 1 | 6.48 | -218.5 | -211.4 | -192.1 | -15.96 | 10.07 | -208 | -70.66 | -164.1 | -14.26 | -45.62 | -31.65 | -1.639 | 59.07 |
| Net income 1 | 10.84 | -219.2 | -207 | -192.4 | -9.111 | -3.681 | -187.5 | -91.93 | -168.4 | -18.37 | -47.16 | -33.45 | -3.454 | 57.2 |
| Net margin | 5.47% | -702.47% | -416.31% | -300.67% | -3.5% | -0.86% | -98% | -34.13% | -57.15% | -4.07% | -12.31% | -7.7% | -0.67% | 9.19% |
| EPS 2 | - | - | - | -3.620 | -0.1700 | -0.0700 | -3.490 | -1.710 | -3.140 | -0.3400 | -1.059 | -0.0782 | 1.224 | 3.481 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 18/11/21 | 24/02/22 | 18/05/22 | 18/08/22 | 14/11/22 | 23/02/23 | 16/05/23 | 17/08/23 | 07/11/23 | 21/02/24 | - | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 754 | 996 | 742 | 536 | 7.14 | 125 | 1,193 | 3,201 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -89.1 | -482 | -462 | -314 | - | 237 | 1,337 | 2,526 |
| ROE (net income / shareholders' equity) | -4.63% | -43.4% | -45.1% | -46.5% | -84.7% | 21.8% | 111% | 87.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 20.40 | 27.00 | 19.30 | 14.30 | 6.240 | 5.780 | 17.80 | 51.60 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 18.1 | 173 | - | 2.51 | - | 31 | 26.6 | 10.2 |
| Capex / Sales | 9.78% | 19,749.08% | - | 0.31% | - | 1.6% | 0.81% | 0.21% |
| Announcement Date | 14/02/20 | 18/02/21 | 24/02/22 | 23/02/23 | 21/02/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
103.7
SEK
Average target price
208
SEK
Spread / Average Target
+100.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.89% | 508M | |
| +4.06% | 70.44B | |
| +10.97% | 8.94B | |
| -14.44% | 4.75B | |
| +41.60% | 4.5B | |
| +5.96% | 3.85B | |
| +23.46% | 2.38B | |
| -19.32% | 2.34B | |
| -27.04% | 2.2B | |
| +7.97% | 1.96B |
- Stock Market
- Equities
- CALTX Stock
- Financials Calliditas Therapeutics AB
